You are here: Home » Companies ¬Ľ News
EV shift a near-term threat to valuation of 2-wheeler firms: Brokerages
icon-arrow-left
Charting growth: Acute therapy drugs make a comeback in July, shows data
Business Standard

Lupin bets big on inhalation segment, plans to enter Chinese market

Lupin's portfolio and pipeline addresses 70 per cent of the entire market

Topics
Lupin | pharmacy

Sohini Das  |  Mumbai 



Vinita Gupta, chief executive officer (CEO), Lupin
Vinita Gupta, chief executive officer (CEO), Lupin

The $2 billion pharma giant, Lupin, has been slowly building a strong portfolio of inhalation products to tap the complex generics respiratory products market globally. The firm is looking for manufacturing partners to enter the Chinese market with a handful of respiratory products that it has either commercialised in other regulated markets or is in the pipeline.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Tue, August 17 2021. 00:30 IST

RECOMMENDED FOR YOU

.